• Skip to main content
  • Skip to primary sidebar
Pediatric Pulmonology: The Remaining Barriers to Normalcy in Cystic Fibrosis

The Remaining Barriers to Normalcy in Cystic Fibrosis

  • Issues
  • Resources
  • About
  • Contact
  • Search
November 2018

The Remaining Barriers to Normalcy in Cystic Fibrosis IV

Rapid therapeutic advances in CFTR modulator science

By John P. Clancy MD

Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by variants in the gene encoding the cystic fibrosis transmembrane conduction regulator (CFTR) protein. Loss of CFTR function disrupts chloride, bicarbonate and regulation of sodium transport, producing a…

[Read More]

Induced pluripotent stem cells for treating cystic fibrosis: State of the science

By Bette S. Pollard SM, ISSC; Harvey B. Pollard MD, PhD

Induced pluripotent stem cells (iPSCs) are a recently developed technology in which fully differentiated cells such as fibroblasts from individual CF patients can be repaired with [wildtype] CFTR, and reprogrammed to differentiate into fully differentiated cells characteristic of…

[Read More]

Inflammation in cystic fibrosis: An update

By Erica A. Roesch MD; David P. Nichols MD; James F. Chmiel MD, MPH

Inflammation plays a critical role in cystic fibrosis (CF) lung pathology and disease progression making it an active area of research and important therapeutic target. In this review, we explore the most recent research on the major contributors…

[Read More]

Reevaluating approaches to cystic fibrosis pulmonary exacerbations

By Michael S. Schechter MD, MPH

Cystic Fibrosis (CF) lung disease is characterized by intermittent acute episodes of worsening signs, symptoms, and pulmonary function; these so‐called pulmonary exacerbations (PEx) appear to be important drivers of long‐term declines in lung function, quality of life, and…

[Read More]

Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis

By Nour Akil MD; Marianne S. Muhlebach MD

Staphylococcus aureus is one of the earliest bacteria isolated from the respiratory tract in people with cystic fibrosis (CF). Its methicillin resistant form, MRSA, has gained attention due to the rapid increase in the last decades and worse outcomes…

[Read More]

The myriad challenges of respiratory fungal infection in cystic fibrosis

By Michael C. Tracy MD; Richard B. Moss MD

Fungal infection in cystic fibrosis (CF) is a recognized challenge, with many areas requiring further investigation. Consensus definitions exist for allergic bronchopulmonary aspergillus in CF, but the full scope of clinically relevant non‐allergic fungal disease in CF—asymptomatic colonization,…

[Read More]

Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience

By Emily F. Muther; Deepika Polineni; Greg S. Sawicki

Individuals living with cystic fibrosis (CF), and their families, have experienced significant improvements in treatment and related research that have enhanced outcomes and survival. Despite such advancement, the burden of living with CF still exists. Many psychosocial stressors…

[Read More]

« Previous Issue
The Remaining Barriers to Normalcy in Cystic Fibrosis III - November 2017
Next Issue »
The Remaining Barriers to Normalcy in Cystic Fibrosis V - November 2019

Primary Sidebar

PP Cover - November 2018

Pediatric Pulmonology

The Remaining Barriers to Normalcy in Cystic Fibrosis I

October 2015 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis II

October 2016 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis III

November 2017 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis IV

November 2018 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis V

November 2019 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VI

February 2021 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VII

February 2022 · View Articles

Most Viewed Articles

  • Rapid therapeutic advances in CFTR modulator science

  • Reevaluating approaches to cystic fibrosis pulmonary exacerbations

  • Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

  • Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

  • Inflammation in cystic fibrosis: An update

Quiz and Survey

Test your knowledge and help shape future editions of "The Remaining Barriers to Normalcy." Participate in our Quiz and Survey »

This website is made possible by an educational grant from Vertex Pharmaceuticals Incorporated.

Vertex

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2018-2025 John Wiley & Sons, Inc. All Rights Reserved.
The content on this site is intended for health professionals.
Wiley